← Leaderboards
Albert Sidney Baldwin
University Of North Carolina Chapel Hill
$25,224,800
Attributed
$28,673,621
Total exposure
17
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,673,621 · 17
By mechanism
R01$11,429,389 · 6
R35$5,767,896 · 1
U01$4,598,428 · 1
R37$3,201,986 · 1
P50$1,753,760 · 4
T32$1,179,190 · 1
Top collaborators
- Catherine T Flores4 shared
- Scott R Floyd4 shared
- Shawn Hingtgen4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- James Campbell Cusack$2,265,526
- Elizabeth C Dees$8,557,163
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionSignal TransductionPathway InteractionsResponseGenesMalignant NeoplasmsTranscription FactorCellsApoptosisPhosphorylationNf-Kappa BTumorInhibitor/AntagonistProteinsBaseResistanceRegulationAnimal ModelCancer TherapyAnimalsResearch StudyPhenotypeMolecularNuclear Factor Kappa Beta
Grant awards (90)
SToP Cancer SPORE: Developmental Research Program$127,340
P50 · FY2025 · CA · contact PI
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform$1,117,537
U01 · FY2024 · TR
SToP Cancer SPORE: Developmental Research Program$122,240
P50 · FY2024 · CA · contact PI
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform$1,135,383
U01 · FY2023 · TR
Function and Mechanism of TET Regulation of Tumor Immunity$313,048
R01 · FY2023 · CA · contact PI
SToP Cancer SPORE: Developmental Research Program$120,543
P50 · FY2023 · CA · contact PI
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform$1,150,319
U01 · FY2022 · TR
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$743,033
R35 · FY2022 · CA · contact PI
Function and Mechanism of TET Regulation of Tumor Immunity$313,048
R01 · FY2022 · CA · contact PI
SToP Cancer SPORE: Developmental Research Program$120,575
P50 · FY2022 · CA · contact PI
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform$1,195,189
U01 · FY2021 · TR
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$814,121
R35 · FY2021 · CA · contact PI
Function and Mechanism of TET Regulation of Tumor Immunity$319,436
R01 · FY2021 · CA · contact PI
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$848,325
R35 · FY2020 · CA · contact PI
Function and Mechanism of TET Regulation of Tumor Immunity$319,436
R01 · FY2020 · CA · contact PI
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$817,442
R35 · FY2019 · CA · contact PI
Function and Mechanism of TET Regulation of Tumor Immunity$319,436
R01 · FY2019 · CA · contact PI
OTUB1 as a Novel Therapeutic Target in Kidney Cancer by Deubiquitinating HIF2alpha$196,840
R21 · FY2019 · CA · contact PI
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$848,325
R35 · FY2018 · CA · contact PI
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$848,325
R35 · FY2017 · CA · contact PI
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells$848,325
R35 · FY2016 · CA · contact PI
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB$287,693
R01 · FY2014 · CA · contact PI
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB$244,798
R01 · FY2014 · CA · contact PI
Control of NF-kappaB Activity$305,308
R37 · FY2013 · AI · contact PI
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB$278,795
R01 · FY2013 · CA · contact PI
Cancer-Associated, Interdependent Regulation of mTOR, AKT, and IKK/NF-kappaB$277,527
R01 · FY2013 · CA · contact PI
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB$237,227
R01 · FY2013 · CA · contact PI
Control of NF-kappaB Activity$324,795
R37 · FY2012 · AI · contact PI
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB$296,590
R01 · FY2012 · CA · contact PI
Cancer-Associated, Interdependent Regulation of mTOR, AKT, and IKK/NF-kappaB$295,242
R01 · FY2012 · CA · contact PI
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB$252,369
R01 · FY2012 · CA · contact PI
Surgical Oncology Research Training Grant$120,189
T32 · FY2012 · CA · contact PI
Control of NF-kappaB Activity$324,795
R37 · FY2011 · AI · contact PI
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB$296,590
R01 · FY2011 · CA · contact PI
Cancer-Associated, Interdependent Regulation of mTOR, AKT, and IKK/NF-kappaB$295,242
R01 · FY2011 · CA · contact PI
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB$252,369
R01 · FY2011 · CA · contact PI
Surgical Oncology Research Training Grant$99,782
T32 · FY2011 · CA · contact PI
Surgical Oncology Research Training Grant$58,365
T32 · FY2011 · CA · contact PI
Control of NF-kappaB Activity$328,075
R37 · FY2010 · AI · contact PI
Regulation of Basal-Like and Her2+ Breast Cancer Phenotypes by IKK/NF-kappaB$305,763
R01 · FY2010 · CA · contact PI
Cancer-Associated, Interdependent Regulation of mTOR, AKT, and IKK/NF-kappaB$304,373
R01 · FY2010 · CA · contact PI
Ras-Induced Lung Cancer: Key Roles for IKK and NF-kappaB$260,174
R01 · FY2010 · CA · contact PI
Surgical Oncology Research Training Grant$122,840
T32 · FY2010 · CA · contact PI
Surgical Oncology Research Training Grant$54,512
T32 · FY2010 · CA · contact PI
Control of NF-kappaB Activity$330,835
R37 · FY2009 · AI · contact PI
Cancer-Associated, Interdependent Regulation of mTOR, AKT, and IKK/NF-kappaB$304,118
R01 · FY2009 · CA · contact PI
Surgical Oncology Research Training Grant$105,574
T32 · FY2009 · CA · contact PI
MOLECULAR CHANGES IN THE NKFB PATHWAY IN RESPONSE TO CHEMORADIATION THERAPY IN RE$341,169
P50 · FY2008 · CA · contact PI
Unexpected Nucleosomal Functions for the IKKs$304,288
R37 · FY2008 · AI · contact PI
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras$249,182
R01 · FY2008 · CA · contact PI
Surgical Oncology Research Training Grant$104,371
T32 · FY2008 · CA · contact PI
MOLECULAR CHANGES IN THE NKFB PATHWAY IN RESPONSE TO CHEMORADIATION THERAPY IN RE$339,285
P50 · FY2007 · CA · contact PI
Unexpected Nucleosomal Functions for the IKKs$310,181
R37 · FY2007 · AI · contact PI
NF-kappaB as a Therapeutic Target for Prostate Cancer$291,570
R01 · FY2007 · CA · contact PI
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras$249,182
R01 · FY2007 · CA · contact PI
Unexpected Nucleosomal Functions for the IKKs$319,445
R37 · FY2006 · AI · contact PI
NF-kappaB as a Therapeutic Target for Prostate Cancer$300,278
R01 · FY2006 · CA · contact PI
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras$256,624
R01 · FY2006 · CA · contact PI
MOLECULAR CHANGES IN THE NKFB PATHWAY IN RESPONSE TO CHEMORADIATION THERAPY IN RE$203,950
P50 · FY2006 · CA · contact PI
Surgical Oncology Research Training Program$101,010
T32 · FY2006 · CA · contact PI
Unexpected Nucleosomal Functions for the IKKs$327,132
R37 · FY2005 · AI
NF-kappaB as a Therapeutic Target for Prostate Cancer$307,504
R01 · FY2005 · CA
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras$262,800
R01 · FY2005 · CA
MOLECULAR CHANGES IN THE NKFB PATHWAY IN RESPONSE TO CHEMORADIATION THERAPY IN RE$192,034
P50 · FY2005 · CA
Surgical Oncology Research Training Program$112,344
T32 · FY2005 · CA
Unexpected Nucleosomal Functions for the IKKs$327,132
R37 · FY2004 · AI
NF-kappaB as a Therapeutic Target for Prostate Cancer$307,504
R01 · FY2004 · CA
Unusual Regulation of the NF-kappaB/IKK Pathway by Ras$262,800
R01 · FY2004 · CA
MOLECULAR CHANGES IN THE NKFB PATHWAY IN RESPONSE TO CHEMORADIATION THERAPY IN RE$186,624
P50 · FY2004 · CA
NF-kappaB Regulation by Androgen Receptor$146,000
R21 · FY2004 · DK
Surgical Oncology Research Training Program$91,797
T32 · FY2004 · CA
NF-kappaB as a Therapeutic Target for Prostate Cancer$307,504
R01 · FY2003 · CA
CONTROL OF TNF SIGNALING BY NFKB$256,255
R01 · FY2003 · AI
NF-kappa beta in mRNA Stability and Cell Differentiation$254,132
R21 · FY2003 · AI
NF-kappaB Regulation by Androgen Receptor$146,000
R21 · FY2003 · DK
Surgical Oncology Research Training Program$109,021
T32 · FY2003 · CA
ANTIAPOPTOTIC MECHANISMS IN PROSTATE CANCER$278,673
R01 · FY2002 · CA
CONTROL OF TNF SIGNALING BY NFKB$248,790
R01 · FY2002 · AI
ROLE FOR NF-KAPPA B IN RAS-MEDIATED ONCOGENESIS$220,186
R01 · FY2002 · CA
Surgical Oncology Research Training Program$99,385
T32 · FY2002 · CA
INHIBITION OF CHEMOTHERAPY INDUCED NFKB$0
P50 · FY2002 · CA
ANTIAPOPTOTIC MECHANISMS IN PROSTATE CANCER$270,556
R01 · FY2001 · CA
CONTROL OF TNF SIGNALING BY NFKB$241,543
R01 · FY2001 · AI
REGULATION OF BCL2 BY RAS AND TUMOR SUPPRESSORS$216,419
R01 · FY2001 · CA
ROLE FOR NF-KAPPA B IN RAS-MEDIATED ONCOGENESIS$213,898
R01 · FY2001 · CA
INHIBITION OF CHEMOTHERAPY INDUCED NFKB$0
P50 · FY2001 · CA
ANTIAPOPTOTIC MECHANISMS IN PROSTATE CANCER$262,675
R01 · FY2000 · CA
CONTROL OF TNF SIGNALING BY NFKB$234,508
R01 · FY2000 · AI
REGULATION OF BCL2 BY RAS AND TUMOR SUPPRESSORS$210,117
R01 · FY2000 · CA
ROLE FOR NF-KAPPA B IN RAS-MEDIATED ONCOGENESIS$207,547
R01 · FY2000 · CA